Allergy Therapeutics Net Asset Quality Index
Allergy Therapeutics net asset quality index. Allergy Therapeutics (AGY) has a Net Asset Quality Index of 6.0% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of GBX71.00 Million minus total liabilities of GBX66.75 Million yields net assets of GBX4.25 Million. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Allergy Therapeutics for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Allergy Therapeutics (2002–2025)
Net asset quality index of Allergy Therapeutics from 2002 to 2025. This chart shows how Allergy Therapeutics's Net Asset Quality Index has evolved across 24 annual periods from 2002 to 2025. As of December 2025, the index stands at 6.0%, representing net assets of GBX4.25 Million against total assets of GBX71.00 Million GBX. Check AGY strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Allergy Therapeutics Net Asset Quality Index by Year (2002–2025)
Allergy Therapeutics net asset quality index by year from 2002 to 2025. The table below presents the year-by-year Net Asset Quality Index for Allergy Therapeutics from 2002 to 2025, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Allergy Therapeutics (AGY) market capitalisation.
| Year | Quality Index | Net Assets (GBX) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -41.7% | GBX-28.19 Million | GBX67.54 Million | GBX95.74 Million | ▼ -47.5 pp |
| 2024 | 5.7% | GBX3.71 Million | GBX64.83 Million | GBX61.12 Million | ▲ +2.6 pp |
| 2023 | 3.1% | GBX2.07 Million | GBX66.77 Million | GBX64.70 Million | ▼ -48.7 pp |
| 2022 | 51.8% | GBX37.77 Million | GBX72.95 Million | GBX35.18 Million | ▼ -3.3 pp |
| 2021 | 55.1% | GBX48.53 Million | GBX88.09 Million | GBX39.55 Million | ▲ +4.3 pp |
| 2020 | 50.8% | GBX43.78 Million | GBX86.22 Million | GBX42.44 Million | ▼ -4.1 pp |
| 2019 | 54.8% | GBX37.56 Million | GBX68.50 Million | GBX30.94 Million | ▲ +9.7 pp |
| 2018 | 45.2% | GBX23.03 Million | GBX51.02 Million | GBX27.98 Million | ▼ -7.3 pp |
| 2017 | 52.4% | GBX29.96 Million | GBX57.18 Million | GBX27.22 Million | ▼ -1.1 pp |
| 2016 | 53.5% | GBX30.32 Million | GBX56.68 Million | GBX26.36 Million | ▼ -14.5 pp |
| 2015 | 68.0% | GBX34.47 Million | GBX50.70 Million | GBX16.23 Million | ▲ +14.9 pp |
| 2014 | 53.1% | GBX15.07 Million | GBX28.40 Million | GBX13.32 Million | ▲ +2.4 pp |
| 2013 | 50.7% | GBX14.67 Million | GBX28.96 Million | GBX14.29 Million | ▼ -1.9 pp |
| 2012 | 52.6% | GBX14.59 Million | GBX27.75 Million | GBX13.16 Million | ▲ +45.6 pp |
| 2011 | 7.0% | GBX2.14 Million | GBX30.62 Million | GBX28.48 Million | ▼ -6.4 pp |
| 2010 | 13.3% | GBX3.89 Million | GBX29.11 Million | GBX25.23 Million | ▲ +118.3 pp |
| 2009 | -105.0% | GBX-23.18 Million | GBX22.08 Million | GBX45.25 Million | ▼ -56.3 pp |
| 2008 | -48.7% | GBX-11.29 Million | GBX23.18 Million | GBX34.47 Million | ▼ -84.5 pp |
| 2007 | 35.8% | GBX8.60 Million | GBX23.99 Million | GBX15.40 Million | ▼ -50.5 pp |
| 2006 | 86.3% | GBX32.70 Million | GBX37.88 Million | GBX5.18 Million | ▲ +11.0 pp |
| 2005 | 75.3% | GBX20.08 Million | GBX26.66 Million | GBX6.58 Million | ▲ +12.3 pp |
| 2004 | 63.0% | GBX7.08 Million | GBX11.23 Million | GBX4.16 Million | ▲ +13.2 pp |
| 2003 | 49.8% | GBX5.55 Million | GBX11.15 Million | GBX5.60 Million | ▲ +95.2 pp |
| 2002 | -45.5% | GBX-4.40 Million | GBX9.68 Million | GBX14.07 Million | — |